Engineered immune cells take aim at Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial tests a new therapy called NW-101C, which uses a patient's own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells carrying a protein called PRAME. The study will enroll 24 adults with advanced solid tumors that h…
Phase: PHASE1 • Sponsor: Neowise Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC